1. Cancer Biology
Download icon

Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

  1. Stephen K Horrigan
  2. Reproducibility Project: Cancer Biology  Is a corresponding author
  1. Noble Life Sciences, United States
Replication Study
Cite this article as: eLife 2017;6:e18173 doi: 10.7554/eLife.18173
3 figures and 1 table

Figures

Figure 1 with 1 supplement
Blood toxicity analysis.

Female FVB mice bearing orthotopic MT1A2 breast tumors were randomized to receive IgG isotype control (IgG) (n = 7) or anti-mouse CD47 (CD47) (n = 7) antibodies. Mice bearing small or undetectable tumors were designated for baseline reading (NT) (n = 6). Five days after the beginning of treatment blood samples collected via retro-orbital bleed were analyzed on a hematology analyzer. Dot plots with means reported as crossbars for each hematological parameter. For each parameter a one-way ANOVA was performed and the alpha level or p-value was adjusted using the Bonferroni correction. (A) White blood cells (WBC), one-way ANOVA; F(2,17) = 15.09, uncorrected p=0.00017 with alpha level = 0.0033; (Bonferroni corrected p=0.0026). (B) Neutrophils (NE), one-way ANOVA; F(2,17) = 1.02, uncorrected p=0.381 with alpha level = 0.0033; (Bonferroni corrected p>0.99). (C) Lymphocytes (LY), one-way ANOVA; F(2,17) = 20.84, uncorrected p=2.67×10−5 with alpha level = 0.0033; (Bonferroni corrected p=0.00040). (D) Monocytes (MO), Welch's one-way ANOVA; F(2,8.52) = 9.98, uncorrected p=0.0058 with alpha level = 0.0033; (Bonferroni corrected p=0.0877). (E) Eosinophils (EO), one-way ANOVA; F(2,17) = 0.06, uncorrected p=0.942 with alpha level = 0.0033; (Bonferroni corrected p>0.99). (F) Basophils (BA), one-way ANOVA; F(2,17) = 4.20, uncorrected p=0.0330 with alpha level = 0.0033; (Bonferroni corrected p=0.495). (G) Red blood cells (RBC), one-way ANOVA; F(2,17) = 424.9, uncorrected p=3.07×10−15 with alpha level = 0.0033; (Bonferroni corrected p=4.60×10−14). (H) Hemoglobin (Hb), one-way ANOVA; F(2,17) = 502.1, uncorrected p=7.61×10−16 with alpha level = 0.0033; (Bonferroni corrected p=1.14×10−14). (I) Hematocrit (HCT), one-way ANOVA; F(2,17) = 283.0, uncorrected p=8.93×10−14 with alpha level = 0.0033; (Bonferroni corrected p=1.34×10−12). (J) Mean corpuscular volume (MCV), one-way ANOVA; F(2,17) = 11.81, uncorrected p=0.00061 with alpha level = 0.0033; (Bonferroni corrected p=0.0091). (K) Mean corpuscular hemoglobin (MCH), one-way ANOVA; F(2,17) = 10.64, uncorrected p=0.00101 with alpha level = 0.0033; (Bonferroni corrected p=0.0151). (L) Mean corpuscular hemoglobin concentration (MCHC), one-way ANOVA; F(2,17) = 0.61, uncorrected p=0.552 with alpha level = 0.0033; (Bonferroni corrected p>0.99). (M) Red blood cell distribution width (RDW), Welch's one-way ANOVA; F(2,10.46) = 30.62, uncorrected p=4.25×10−5 with alpha level = 0.0033; (Bonferroni corrected p=0.00064). (N) Platelets (PLT), one-way ANOVA; F(2,17) = 0.62, uncorrected p=0.548 with alpha level = 0.0033; (Bonferroni corrected p>0.99). (O) Mean platelet volume (MPV), one-way ANOVA; F(2,17) = 6.98, uncorrected p=0.0061 with alpha level = 0.0033; (Bonferroni corrected p=0.092). Additional details for this experiment can be found at https://osf.io/g57ch/.

https://doi.org/10.7554/eLife.18173.002
Figure 1—figure supplement 1
Blood toxicity analysis.

Female FVB mice bearing orthotopic MT1A2 breast tumors were randomized to receive IgG isotype control (IgG) (n = 7) or anti-mouse CD47 (CD47) (n = 7) antibodies. Mice bearing small or undetectable tumors were designated for baseline reading (NT) (n = 6). Five days after the beginning of treatment blood samples collected via retro-orbital bleed were analyzed on a hematology analyzer. Normal reference ranges (Range) for each parameter are from Drew Scientific Hemavet 950FS. WBC = White blood cells; NE = Neutrophils; LY = Lymphocytes; MO = Monocytes; EO = Eosinophils; BA = Basophils; RBC = Red blood cells; Hb = Hemoglobin; HCT = Hematocrit; MCV = Mean corpuscular volume; MCH = Mean corpuscular hemoglobin; MCHC = Mean corpuscular hemoglobin concentration; RDW = Red blood cell distribution width; PLT = Platelets; MPV = Mean platelet volume. Additional details for this experiment can be found at https://osf.io/g57ch/.

https://doi.org/10.7554/eLife.18173.003
Figure 2 with 1 supplement
Final tumor weights of immune competent hosts treated with control or CD47 targeted antibodies.

At the end of the predefined study period (Day 31), tumors from mice bearing orthotopic MT1A2 breast tumors treated every other day with IgG isotype control (IgG) (n = 7) or anti-mouse CD47 (anti-CD47) (n = 6) antibodies were excised and weighed. Dot plot with means reported as crossbars and error bars represent s.e.m. Two-tailed Welch’s t-test between IgG and anti-CD47 treated tumors; t(9.66) = 1.796, p=0.104. Additional details for this experiment can be found at https://osf.io/g57ch/.

https://doi.org/10.7554/eLife.18173.004
Figure 2—figure supplement 1
Tumor volumes of immune competent hosts treated with control or CD47 targeted antibodies.

This is the same experiment as in Figure 2. Following orthotopic injection of MT1A2 cells mice were monitored for development of tumors. Caliper measurements were taken at 9, 11, 18, and 25 days after cell injection to calculate tumor volume. Fourteen mice with detectable tumors were randomly assigned to treatment at 11 days post cell inoculation (dashed line). At the end of the predefined study period, tumors from mice treated with either IgG isotype control (IgG) (n = 7) or anti-mouse CD47 (anti-CD47) (n = 6) antibodies were excised and weighed. Tumor volume at day 42 post cell injection was calculated from weight and density (1.05 g/ml). Exploratory analysis on tumor weights excluding three tumors that regressed during the course of the study (indicated by asterisk): two-tailed Welch’s t-test between IgG and anti-CD47 treated tumors; t(7.94) = 0.745, p=0.478, Glass' =Δ −0.58, 95% CI [−1.88, 0.80]. Additional details for this experiment can be found at https://osf.io/g57ch/.

https://doi.org/10.7554/eLife.18173.005
Meta-analysis of effect.

Effect size (Glass' Δ) and 95% confidence interval are presented for Willingham et al. (2012), this replication attempt (RP:CB), and a meta-analysis to combine the two effects of tumor weight comparisons. Sample sizes used in Willingham et al. (2012) and this replication attempt are reported under the study name. Random effects meta-analysis of tumors treated with IgG compared to anti-CD47 (meta-analysis p=0.745). Additional details for this meta-analysis can be found at https://osf.io/ha2bx/.

https://doi.org/10.7554/eLife.18173.007

Tables

Table 1

Severity of inflammatory cell infiltration of tumors. Excised tumors were fixed, sectioned, and stained with hematoxylin and eosin and blindly scored by a Board Certified pathologist utilizing the severity score for inflammatory cell infiltrates (Demaria et al., 2001). Tumor infiltrating lymphocytes and neutrophils were scored for tumors from mice bearing orthotopic MT1A2 breast tumors treated every other day with IgG isotype control (IgG) (n = 7) or anti-mouse CD47 (CD47) (n = 6) antibodies. Additional details for this experiment can be found at https://osf.io/g57ch/.

https://doi.org/10.7554/eLife.18173.006
Lymphocytic infiltrateNeutrophilic infiltrate
TreatmentAbsentMinimalModerateBriskAbsentMinimalModerateBrisk
IgG06100430
CD4705100132

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)